Hagens berman: 29 days remain before june 25, 2013, lead plaintiff
deadline in intuitive surgical, inc., securities lawsuit
Berkeley, calif.--(business wire)--hagens berman sobol shapiro llp, a national investor-rights law firm, today reminded investors that 29 days remain before the june 25, 2013, lead plaintiff deadline in a securities class-action lawsuit brought against intuitive surgical, inc. (nasdaq: isrg) (“isrg” or “the company”). those who have more than $300,000 in losses are encouraged to contact a hagens berman attorney to discuss moving for lead plaintiff in the case by emailing isrg@hbsslaw.com or calling (510) 725-3000. investors who purchased isrg common stock between oct. 19, 2011, and april 18, 2013, (the “class period”) and have suffered significant losses can also reach hagens berman partner reed r. kathrein, who is leading the firm’s investigation, by visiting http://www.hb-securities.com/investigations/isrg. investors who wish to serve as lead plaintiff in the case must move the court no later than june 25, 2013. any member of the putative class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. on april 26, 2013, a lawsuit was filed in the u.s. district court for the northern district of california, alleging that isrg issued a series of false or misleading statements to investors during the class period. the suit alleges that isrg failed to fully disclose to investors the financial impact of safety problems with its da vinci surgical system, including a number of deaths allegedly caused by the system. on april 30, 2013, medscape—an online medical resource for healthcare professionals—reported that the food and drug administration has begun to investigate da vinci following a spike in adverse event reports (aers) related to the system’s use in surgery. according to medscape, the number of da vinci aers filed with the fda increased by 34 percent between 2011 and 2012. a number of lawsuits have been filed against the company seeking damages for injuries allegedly caused by da vinci. isrg’s stock price suffered a significant decline following media coverage of those suits. the filed investor lawsuit claims that isrg deceived investors regarding the risk of fda action against the company. hagens berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the securities and exchange commission. under the new sec whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the sec. about hagens berman hagens berman sobol shapiro llp is an investor-rights class-action law firm with offices in 10 cities. the firm represents investors, whistleblowers, workers and consumers in complex litigation. more about the law firm and its successes can be found at www.hbsslaw.com. the firm’s securities law blog is at http://www.meaningfuldisclosure.com.
ISRG Ratings Summary
ISRG Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission